BioMarin Pharmaceutical (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction dated Tuesday, April 17th. The shares were sold at an average price of $85.00, for a total value of $318,750.00. Following the sale, the director now owns 18,610 shares in the company, valued at approximately $1,581,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of BMRN traded up $0.08 during trading hours on Friday, hitting $83.70. The company had a trading volume of 56,842 shares, compared to its average volume of 1,325,967. BioMarin Pharmaceutical has a 52-week low of $75.81 and a 52-week high of $100.51. The company has a market cap of $14,864.02, a P/E ratio of -124.81 and a beta of 1.69. The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.29.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. The business had revenue of $358.31 million for the quarter, compared to analysts’ expectations of $346.24 million. equities research analysts forecast that BioMarin Pharmaceutical will post -0.16 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in BMRN. First Manhattan Co. increased its holdings in BioMarin Pharmaceutical by 104.2% during the 4th quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 625 shares during the period. Financial Gravity Companies Inc. purchased a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $112,000. IFG Advisory LLC purchased a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $212,000. First Republic Investment Management Inc. purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $220,000. Finally, Redmile Group LLC purchased a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $223,000.
A number of equities research analysts have weighed in on the company. BMO Capital Markets restated an “outperform” rating and set a $125.00 price target (up previously from $119.00) on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Wedbush restated an “outperform” rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, December 22nd. Credit Suisse Group restated a “buy” rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, March 29th. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Finally, JPMorgan Chase restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Sunday, February 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $112.34.
COPYRIGHT VIOLATION NOTICE: “BioMarin Pharmaceutical (BMRN) Director V Bryan Lawlis Sells 3,750 Shares” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://macondaily.com/2018/04/20/biomarin-pharmaceutical-bmrn-director-v-bryan-lawlis-sells-3750-shares.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.